All Episodes
|
52
|
John Marchica

Episode 52: Our Take, June 3, 2019

Jun 3, 2019

Episode Summary

In this week’s episode, John reviews Novartis’ new gene therapy for spinal muscular atrophy, priced at more than $2.1 million. ICER, a nonprofit research institute that evaluates the cost effectiveness of pharmaceuticals, said Novartis’ price is within the upper bound of the organization’s value-based price benchmark range.

Episode Notes

In this week’s episode, John reviews Novartis’ new gene therapy for spinal muscular atrophy, priced at more than $2.1 million. ICER, a nonprofit research institute that evaluates the cost effectiveness of pharmaceuticals, said Novartis’ price is within the upper bound of the organization’s value-based price benchmark range.

Briefs include:

  • A broad bipartisan draft health care legislation package containing dozens of provisions was recently released by the Senate Health Committee.
  • Forcing oncology practices to take on downside risk in CMS’ Oncology Care Model in July could result in more than half of them owing the government.
  • UnitedHealth Group pointed to price variations for diagnostic tests as a potential way to reduce overspending.
  • Mallinckrodt plans to spin off its specialty generics business to shareholders.
  • The FDA’s recent approval of Novartis’ Piqray (alpelisib).
  • FDA clears a new wearable device to treat migraine.
  • Biogen is scrapping its investigational treatment for Alzheimer’s disease, and is canceling its Phase III ENGAGE and EMERGE clinical trials.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs
Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare
Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health
Podcast 194: Why Health Care Reform Keeps Failing w/ Dr. David Shulkin
Podcast 193: The New Model for Specialty Pharmacy w/ Jigar Thakkar, PharmD
Podcast 192: Making Value-Based Care Work at Scale w/ David Carmouche, MD
Podcast 191: Curing Nursing Burnout Through Education w/ Dr. Adele Webb
Podcast 190: The New Rules of Health System Leadership w/ John D’Angelo, MD, FACEP

Recommended Content

Browse Library
INsights
January 14, 2026

Darwin's Our Take: Lilly’s ‘triple G’ candidate exceeds analysts’ expectations

Read More
INsights
January 11, 2026

Darwin's Our Take: OpenAI introduces ChatGPT Health to further integrate users' health information

Read More
INsights
January 5, 2026

Darwin's Our Take: FDA approves Novo Nordisk’s Wegovy pill

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.